How has been the historical performance of Natco Pharma?

Answer:The historical performance of Natco Pharma shows a significant upward trend in net sales and profitability over the years, culminating in the fiscal year ending March 2025.

Breakdown:
Natco Pharma's net sales have increased from 1,915.00 Cr in March 2020 to 4,429.50 Cr in March 2025, reflecting a strong growth trajectory. The total operating income followed a similar pattern, rising from 1,915.00 Cr in March 2020 to 4,429.50 Cr in March 2025. Operating profit (PBDIT) also saw substantial growth, reaching 2,550.50 Cr in March 2025, up from 690.00 Cr in March 2020. Profit before tax increased from 568.70 Cr in March 2020 to 2,291.40 Cr in March 2025, while profit after tax rose from 458.10 Cr to 1,883.40 Cr in the same period. The company's earnings per share (EPS) surged from 25.32 in March 2020 to 105.33 in March 2025, indicating improved shareholder value. On the balance sheet, total assets increased from 4,587.80 Cr in March 2020 to 8,580.70 Cr in March 2025, alongside total liabilities rising from 4,587.80 Cr to 8,580.70 Cr. The cash flow from operating activities improved significantly, reaching 1,696.00 Cr in March 2025, compared to 417.00 Cr in March 2020. Overall, Natco Pharma has demonstrated robust growth in revenue and profitability, alongside a healthy cash flow position over the years.